Physician profile
Sergey Kantsevoy
NPI 1912954181
$1,097,809.30
in general payments reported to CMS, 2019-2025
61 companies · $113K in 2025
The $113K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $245K · 2020: $173K · 2021: $147K · 2022: $165K · 2023: $117K · 2024: $138K · 2025: $113K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $159K · Consulting Fee: $151K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Travel and Lodging: $18K · Grant: $10K · Food and Beverage: $5,995.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $158,962.62 |
| Consulting Fee | $150,953.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,000.00 |
| Travel and Lodging | $17,711.49 |
| Grant | $10,000.00 |
| Food and Beverage | $5,995.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumendi LLC | $689,589.66 | 2019-2025 | Dilumen Endolumenal Interventional Platform |
| Olympus Corporation of The Americas | $350,516.01 | 2019-2025 | Olympus, Single Use Electrosurgical Knife Kd-655, Disposable Distal Attachment |
| Olympus America INC. | $25,626.10 | 2019-2024 | Single Use Electrosurgical Knife Kd-655, Endoclot Phs |
| Erbe USA INC | $10,123.11 | 2024-2025 | Vio3 |
| Fujifilm Healthcare Americas Corporation | $8,184.55 | 2023-2025 | Fujifilm |
| Covidien Lp | $4,250.00 | 2020 | |
| Abbvie INC. | $1,877.36 | 2019-2025 | |
| Apollo Endosurgery US INC | $1,000.00 | 2019 | |
| Olympus Corporation | $615.00 | 2024 | Single Use Electrosurgical Knife Kd-655 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $539.70 | 2019-2025 | Xifaxan, Trulance |
| Boston Scientific Corporation | $436.67 | 2019-2023 | |
| Intercept Pharmaceuticals, INC. | $374.40 | 2019-2025 | Ocaliva |
| Qol Medical, LLC | $327.50 | 2021-2024 | Sucraid, Sucraid |
| Micro-Tech Endoscopy USA, INC. | $275.44 | 2024 | Dat Device |
| Mallinckrodt Hospital Products INC. | $265.19 | 2022-2025 | Terlivaz |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Conmed Corporation | $260.06 | 2021 | |
| Medtronic, INC. | $249.34 | 2021-2025 | Endoflip, Interstim |
| Madrigal Pharmaceuticals | $217.84 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $201.48 | 2021-2025 | Gattex |
| Eisai INC. | $198.06 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $173.26 | 2021-2023 | |
| Genzyme Corporation | $154.71 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $145.55 | 2019-2024 | Rebyota |
| Aimmune Therapeutics, INC. | $143.67 | 2023-2025 | Vowst, Zenpep |
| Phathom Pharmaceuticals, INC. | $139.02 | 2024-2025 | Voquezna |
| Shionogi INC | $132.57 | 2019-2020 | |
| Pentax of America, INC. | $132.31 | 2022 | |
| Exelixis INC. | $130.42 | 2019-2022 | |
| Cook Medical LLC | $126.98 | 2025 | Hemospray |
| Digestive Care, INC. | $120.91 | 2021-2025 | Pertzye |
| Ardelyx, INC. | $118.31 | 2022-2023 | Ibsrela |
| Alnylam Pharmaceuticals INC. | $110.21 | 2023-2025 | Givlaari |
| Ambu INC. | $92.62 | 2021 | |
| Ironwood Pharmaceuticals, INC | $90.69 | 2022-2023 | Linzess |
| Braintree Laboratories, INC. | $55.40 | 2021-2023 | Sutab, Suflave |
| Pfizer INC. | $52.51 | 2019-2023 | |
| Lilly USA, LLC | $51.36 | 2024 | Omvoh |
| Janssen Biotech, INC. | $47.52 | 2024 | Stelara |
| Ucb, INC. | $47.41 | 2019 | |
| Romark Laboratories, Lc | $46.90 | 2019-2020 | |
| Organon LLC | $42.32 | 2023-2024 | Hadlima, Renflexis |
| Dynavax Technologies Corporation | $42.23 | 2019-2022 | |
| Redhill Biopharma INC. | $41.32 | 2021 | |
| Vivus LLC | $40.54 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $36.80 | 2022-2025 | Dupixent |
| Dova Pharmaceuticals | $35.40 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $33.69 | 2022-2023 | |
| Gilead Sciences, INC. | $29.92 | 2022 | |
| Ethicon US, LLC | $27.98 | 2023 | Enseal X1, Echelon Flex |
| Daiichi Sankyo INC. | $27.13 | 2022 | |
| Incyte Corporation | $25.96 | 2023 | Pemazyre |
| Ipsen Biopharmaceuticals, INC | $25.62 | 2024 | Bylvay |
| Evoke Pharma, INC. | $23.95 | 2024 | |
| Teleflex LLC | $22.67 | 2024 | Solesta |
| Albireo Pharma, INC. | $19.50 | 2022 | |
| Novo Nordisk INC | $19.34 | 2025 | Wegovy |
| Mirum Pharmaceuticals, INC. | $16.83 | 2025 | Cholbam, Livmarli, Chenodal |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.15 | 2024 | Cyltezo |
| Cumberland Pharmaceuticals, INC. | $15.91 | 2024 | Sancuso |
| Shire North American Group INC | $13.58 | 2019 | |
| Amag Pharmaceuticals, INC. | $12.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sergey Kantsevoy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.